Matinas Biopharma Holdings Inc. (MTNB)
AMEX AMEX Primary Summary
Matinas BioPharma Holdings, Inc. (MTNB) Q2 2024 Earnings Call Transcript
Matinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Jody Cain – LHA Investor Relations Jerry Jabbour – Chief Executive Officer Keith Kucinski – Chief Financial Officer Terri Matkovits – Chief Development Officer Conference Call Participants Scott Henry – Alliance Global Partners Joanne Lee – Maxim Group Operator Welcome to the Matinas BioPharma Second Quarter 2024 Financial Results Conference Call. Currently all participants are in a listen-only mode.
Matinas Biopharma Holdings Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 14 | $50 | $4.76 | -$45.24 | -90.48% |
 Michael Byun SageView Advisory Group LLC | 10 | $6 | $3.33 | -$2.67 | -44.5% |
 Christopher C. Powers Farther Finance Advisors, LLC | 5 | $9.45 | $1.67 | -$7.78 | -82.33% |
| HIW Holos Integrated Wealth LLC Holos Integrated Wealth LLC | 32,480 | $16,565 | $11,361.5 | -$5,203.5 | -31.41% |
Matinas Biopharma Holdings Inc. (MTNB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Matinas Biopharma Holdings Inc. ever had a stock split?
Matinas Biopharma Holdings Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jerome D. Jabbour CEO | AMEX Exchange | 576810303 CUSIP |
| US Country | 4 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Matinas BioPharma Holdings, Inc. is a proactive clinical-stage biopharmaceutical enterprise that focuses on the discovery and development of drug products facilitated by its proprietary lipid nanocrystal (LNC) platform technology. Positioned in Bedminster, New Jersey, and established in 2013, the company accentuates the utilization of its LNC delivery technology platform. This innovative methodology is adept in harnessing lipid nanocrystals for the efficient conveyance of a diverse array of therapeutic agents such as small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Matinas BioPharma has formed strategic alliances with prominent institutions and companies, including the National Institute of Allergy and Infectious Diseases, BioNTech SE, and Genentech Inc., underscoring its commitment to advancing healthcare through groundbreaking oral formulations and delivery systems.
Products and Services
MAT2203: This leading product candidate epitomizes an oral formulation of amphotericin B, which is on the brink of entering Phase 3 clinical trials. It is primarily focused on the treatment of aspergillosis and cryptococcosis, besides aiming to prevent invasive fungal infections in patients under immunosuppressive therapy. MAT2203 leverages the LNC platform to potentially transform the administration of this powerful antifungal agent, enabling oral delivery that can increase patient compliance and reduce adverse effects associated with traditional intravenous routes.
MAT2501: Another innovative offering in its pipeline, MAT2501, is an orally administered formulation of amikacin that is designed to tackle both chronic and acute bacterial infections, alongside targeting non-tuberculosis mycobacterium (NTM) diseases. Through the novel use of the LNC platform, MAT2501 aspires to deliver a high-impact solution for treating serious bacterial infections with the ease and safety of oral dosing, aiming to mitigate the risks and complexities tied to injectable therapies.
Strategic Collaborations: Matinas BioPharma's notable collaborations reflect its strategic foresight in leveraging external expertise and partnerships to expand its scope of research and development. The collaboration with the National Institute of Allergy and Infectious Diseases is geared towards creating oral formulations of Gilead's remdesivir, an effort accentuating the commitment to fighting viral pandemics with accessible antiviral therapies. Furthermore, partnering with BioNTech SE to explore the combination of mRNA formats with the LNC platform heralds a new frontier in vaccine delivery. Lastly, the alliance with Genentech Inc. aims at developing oral formulations, paving the way for novel therapeutic options that could transcend traditional administration barriers.
